Ιndications for bisphosphonates’ use, as an alternative treatment for
intraosseous lesions Review of the literature
Katherine TRIANTAFILLIDOU, George KARAKINARIS, Gregory VENETIS
Department of Oral and Maxillofacial Surgery, General Hospital “G Papanikolaou” Aristotle University of Thessaloniki, Greece (Head: Professor K. Antoniadis)
Hellenic Archives of Oral & Maxillofacial Surgery (2013) 1, 35-46
SUMMARY: Objectives: The treatment with bisphosphonates is established in controlling bone resorption by inhibition of osteoclast action, due to osteoporosis, multiple myeloma, Paget’s disease and metastatic malignancy. The aim of this review is to present a number of studies, as they are reported in the recent literature, where bisphosphonates have been used with good results as primary or adjunctive treatment. The use of bisphosphonates therapy proved effective for selective cases of giant and eosinophilic cell osseous lesions, fibrous dysplasia, Gaucher’s disease, chronic recurrent multifocal osteomyelitis, osteogenesis imperfect, orthopedic and dental implants. There are however many other intraosseous lesions where a decrease in bone resorption by bisphosphonates could be effective for the management of these bone lesions. Conclusions: Further investigations are needed to determine the potential role of bisphosphonates for the treatment of bone lesions
KEY WORDS: bisphosphonates, fibrous dysplasia, Gaucher’s disease, osteomyelitis, osteogenesis imperfecta, orthopedic implants.
REFERENCES
Abtahi J, Tengvall P, Aspenberg P. A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. Bone. 50(5):1148-51, 2012
Amako M, Fassier F, Hamdy RC, et al: Functional analysis of upper limb deformities in osteogenesis imperfecta. J Pediatr Orthop. 24:689- 94, 2004
Arzoo K, Sadeghi S, Pullarkat V. Pamidronate for bone pain from osteolytic lesions in Langerhans’-cell histiocytosis. N Engl J Med. 345:225, 2001
Ayan M, Dolanmaz D, Mihmanlı A, et al: The effect of systemically administrated zoledronic acid on the osseointegration of dental implants. Oral Dis 18(8):802-8, 2012
Back DA, Pauly S, Rommel L, et al. Effect of local zoledronate on implant osseointegration in a rat model. BMC Musculoskelet Disord. 22;13:42, doi: 10.1186/1471-2474-13-42, 2012.
Bembi B, Deegan P: Gaucher disease: improving management. Acta Paediatr Suppl. 97:81-2, 2008
Bianco P, Riminucci M, Majolagbe A, et al: Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in nonMcCune-Albright fibrous dysplasia of bone. J Bone Miner Res. 15:120-8, 2000
Brånemark PI, Hansson BO, Adell R, et al: Osseointegrated implants in the treatment of the edentulous jaw. Experience from a 10-year period. Scand J Plast Reconstr Surg 16:1-132, 1977
Chang SS, Suratwala SJ, Jung KM, et al:.Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.Clin Orthop Relat Res (426):103-9, 2004
Chao K, Katznelson L: Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull. J Neurosurg. 109:889-92, 2008 Chapurlat RD, Delmas PD, Liens D, Meunier PJ: Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res.12:1746-52, 1997
Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ: Treatment of fibrous dysplasia of bone with intravenous pamidronate: longterm effectiveness and evaluation of predictors of response to treatment. Bone. 35:235-42, 2004
Ciana G, Cuttini M, Bembi B: Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement. N Engl J Med. 337:712, 1997
Compeyrot-Lacassagne S, Rosenberg AM, et al: Pamidronate treatment of chronic noninfectious inflammatory lesions of the mandible in children. J Rheumatol. 34:1585-9, 2007
da Silva NG, Carreira AS, Pedreira EN, et al: Treatment of central giant cell lesions using bisphosphonates with intralesional corticosteroid injections. Head Face Med. 22;8:23. doi: 10.1186/1746-160X-8- 23, 2012
Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C: Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 16:360-3, 1987
DiMeglio LA, Peacock M: Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006 21:132-40, 2006).
Eberhardt C, Stumpf U, Brankamp J, et al: Osseointegration of cementless implants with different bisphosphonate regimens. Clin Orthop Relat Res. 447:195-200, 2006
Elomaa I, Blomqvist C, Porkka L, Holmstrom T. Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone. J Intern Med 225:59–61, 1989
Gallagher KT, Roberts RL, MacFarlane JA, Stiehm ER: Treatment of chronic recurrent multifocal osteomyelitis with interferon gamma. J Pediatr. 131:470-2, 1997
Gibbons CL, Petra M, Smith R, et al: Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone. NA.Sarcoma. 7:35-41, 2003 Giedion A, Holthusen W, Masel LF, Vischer D: Subacute and chronic "symmetrical" osteomyelitis. Ann Radiol (Paris). 15:329-42, 1972
Girschick HJ, Raab P, Surbaum S, et al: Chronic non-bacterial osteomyelitis in children. Ann Rheum Dis. 64:279-85, 2005
Gleeson H, Wiltshire E, Briody J, et al: Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol. 35:707-12, 2008
Glorieux FH, Bishop NJ, Plotkin H, et al: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 339:947-52, 1998
Harinck HI, Bijvoet OL, van der Meer JW, et al: Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate. Lancet. 2(8401):513, 1984
Huber AM, Lam PY, Duffy CM, et al: Chronic recurrent multifocal osteomyelitis: clinical outcomes after more than five years of follow-up. J Pediatr. 141:198-203, 2002
Hughes DE, Wright KR, Uy HL, et al: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.J Bone Miner Res. 10:1478-87, 1995 Kamizono J, Okada Y, Shirahata A, Tanaka Y. Bisphosphonate induces remission of refractory osteolysis in langerhans cell histiocytosis. J Bone Miner Res 17:1926–8, 2002
Kos M, Luczak K, Godzinski J, Klempous J: Treatment of monostotic fibrous dysplasia with pamidronate. J Craniomaxillofac Surg. 32:10-5, 2004
Kim JH, Park YB, Li Z, Shim JS, et al: Effect of alendronate on healing of extraction sockets and healing around implants. Oral Dis. 17(7):705-11, 2011
Kurth AH, Eberhardt C, Müller S, et al: The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone. 37:204-10, 2005
Landesberg R, Eisig S, Fennoy I, Siris E: Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg. 67:27-34, 2009
Lane JM, Khan SN, O'Connor WJ, et al: Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res. 382:6-12, 2001
LianouV, Alexopoulou M, Kanoutos D, et al: Bisphosphonates induced osteonecrosis of the jaws. A clinical study of 21 cases. Hellenic Archives of Oral and Maxillofac Surg 3:141-154, 2011
Löwing K, Aström E, Oscarsson KA, et al: Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. Acta Paediatr. 96:1180-3, 2007
Mäkitie AA, Törnwall J, Mäkitie O: Bisphosphonate treatment in craniofacial fibrous dysplasia--a case report and review of the literature. Clin Rheumatol. 27:809-12, 2008
Marie PJ, de Pollak C, Chanson P, Lomri A: Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol. 150:1059-69, 1997
Montella L, Merola C, Merola G, et al: Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab 27:110–3, 2009 Montonen M, Kalso E, Pylkkären L, et al: Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible. Int J Oral Maxillofac Surg. 30:313-7, 2001
Parisi MS, Oliveri B, Mautalen CA: Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone. 33:582-8, 2003
Poyrazoglu S, Gunoz H, Darendeliler F, et al: Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. J Pediatr Orthop. 28:483-7, 2008
Rogers MJ, Gordon S, Benford HL, et al: Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88:2961-78, 2000 Romanos G, Konsolaki E, Hatzimanolis P: Bisphosphonate-induced osteonecrosis of the jaws. Report of 24 cases. Hellenic Stomatological Review. 53:243-252, 2009
Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 19:733-59, 2008
Samuel R, Katz K, Papapoulos SE, et al: Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics. 94:385-9, 1994
Sato M, Grasser W: Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 5:31-40, 1990
Simm PJ, Allen RC, Zacharin MR: Bisphosphonate treatment in chronic recurrent multifocal osteomyelitis. J Pediatr. 152:571-5, 2008
Sivendran S, Harvey H, Lipton A, Drabick J.: Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series. Int J Hematol. 93(6):782-6, 2011
Suratwala SJ, Cho SK, van Raalte JJ, et al: Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite. J Bone Joint Surg Am. 90:2189-96, 2008
Tapaninen TS, Venesmaa PK, Jurvelin JS, et al: Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients. Scand J Surg. 99:32-7, 2010
Triantafillidou K, Dimitrakopoulos J: Pathogenetic factors in the development of fibrous dysplasia and McCune-Albright Syndrome. Current review of the literature. Balk J Stom 7:77-81, 2003
Tse LF, Wong KC, Kumta SM, et al: Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study. Bone 42:68- 73, 2008
Tsetsenekou E, Kalyvas D: New insights into the mechanisms of bisphosphonates action. Hellenic Archives of Oral and Maxillofac Surg 3:157-166, 2010 Valentini V, Cassoni A, Marianetti TM, et al: Craniomaxillofacial fibrous dysplasia: conservative treatment or radical surgery? A retrospective study on 68 patients. Plast Reconstr Surg. 123:653-60, 2009
Vallo A, Rodriguez-Leyva F, Rodríguez Soriano J: Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr. 95:332-9, 2006
Vasikaran SD: Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 38:608-23, 2001
Venesmaa PK, Kröger HP, Miettinen HJ, et al: Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res. 16:2126-31, 2001
Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B: Skeletal aspects of Gaucher disease: a review. Br J Radiol. 75:A2-12, 2002
Wenstrup RJ, Bailey L, Grabowski GA, et al: Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood. 104:1253-7, 2004
Wermelin K, Suska F, Tengvall P, et al: Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. Bone. 42:365-71, 2008
Yamazaki Y, Satoh C, Ishikawa M, et al: Remarkable response of juvenile diffuse sclerosing osteomyelitis of mandible to pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 104:67-71, 2007
Yip JK, Borrell LN, Cho SC, Francisco H, Tarnow DP: Association between oral bisphosphonate use and dental implant failure among middle-aged women. J Clin Periodontol. 39(4):408-14, 2012.
Zeng Y, Lai O, Shen B, et al: A systematic review assessing the effectiveness of alendronate in reducing periprosthetic bone loss after cementless primary THA. Orthopedics. 11:34, 2011
How to cite this article:
|
View the full-text PDF:
|
| ||